Join groupH’s discussion on TPP Development and Indication Prioritization at the NPP Summit Boston

groupH will talk through 2 project case studies focusing on TPP Development and Indication Prioritization for Biotech companies at pre-clinical or early-stage clinical stage. The talk is aimed at individuals in commercial and non-commercial roles who have to manage uncertainty when aligning on overall scientific and commercial strategy. We will discuss a recent, real-world project process and the trade-offs between different, alternative project approaches. We will dissect the TPP development process and share client views on project timing and project learnings. Participants will leave with key insights from this real-world technology platform development project and there will be time for Q&A at the end.

About Erik Holzinger, groupH:

Erik Holzinger MBA is the founder of groupH a Consulting company dedicated to commercial decision making and analysis. In recent years Erik has been particularly interested in exploring the topics driving TPP development at the more delicate, early stages when commercial and scientific uncertainty is still quite high. Erik is also active as member of the ephmra Annual Conference Organising Committee and co-founder of the ephmra Forecasting Forum. Prior to 2005, he was a Principal Consultant in the Pharmaceuticals and Biotechnology team of Wood Mackenzie and a Consultant at The Wilkerson Group. His mother tongue is German, and he is fluent in English and Spanish and lives in South-West London with his family. Outside of work Erik enjoys spending time with his family, yoga, cycling, windsurfing, skiing and the cultural landscape of London.

Find out more about the NPP Summit Boston, October 16, 2023:

Register for the event:

See full list of speakers:

View full programme:

Any questions just get in touch –

The groupH Team